Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants
about
Molecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted TherapySecondary mutations as mediators of resistance to targeted therapy in leukemiaPlatelet-derived growth factor receptor/platelet-derived growth factor (PDGFR/PDGF) system is a prognostic and treatment response biomarker with multifarious therapeutic targets in cancers.The Cytokine Flt3-Ligand in Normal and Malignant HematopoiesisMolecular therapy for acute myeloid leukaemia.Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemiaThe Biology and Targeting of FLT3 in Pediatric Leukemia.The Future of Targeting FLT3 Activation in AML.Acute myeloid leukemia: 2014 update on risk-stratification and management.FLT3 kinase inhibitor TTT-3002 overcomes both activating and drug resistance mutations in FLT3 in acute myeloid leukemia.Overcoming myelosuppression due to synthetic lethal toxicity for FLT3-targeted acute myeloid leukemia therapy.Computer aided drug discovery of highly ligand efficient, low molecular weight imidazopyridine analogs as FLT3 inhibitors.Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia.Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade.FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitorsThe MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia.Acute myeloid leukemia: advancing clinical trials and promising therapeutics.How I treat FLT3-mutated AML.Molecular therapeutic approaches for pediatric acute myeloid leukemia.Crenolanib is a selective type I pan-FLT3 inhibitorThe implication of FLT3 amplification for FLT targeted therapeutics in solid tumors.FLT3 inhibitors in AML: are we there yet?Novel drugs for older patients with acute myeloid leukemia.Quizartinib for the treatment of FLT3/ITD acute myeloid leukemia.Targeting FLT3 to treat leukemia.Is allogeneic transplantation really the best treatment for FLT3/ITD-positive acute myeloid leukemia? A systematic review.New treatment for acute myelogenous leukemia.Mutations in tyrosine kinase and tyrosine phosphatase and their relevance to the target therapy in hematologic malignancies.Perspectives for therapeutic targeting of gene mutations in acute myeloid leukaemia with normal cytogenetics.Management of Relapsed/Refractory Acute Myeloid Leukemia in the Elderly: Current Strategies and Developments.Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock?FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions.Frontline treatment of acute myeloid leukemia in adults.Blockade of PDGF Receptors by Crenolanib Has Therapeutic Effect in Patient Fibroblasts and in Preclinical Models of Systemic Sclerosis.Treatment of Acute Myeloid Leukemia with the FLT3 Gene Mutation.Pharmacologic maintenance strategies following allogeneic hematopoietic cell transplantation for acute myeloid leukemia.Inhibition of FLT3 in AML: a focus on sorafenib.Treatment of Relapsed/Refractory Acute Myeloid Leukemia.Mechanisms of Resistance to FLT3 Inhibitors and the Role of the Bone Marrow Microenvironment.
P2860
Q26749870-7A31485B-4212-46F2-BD96-8A08BA991FFBQ28087213-746A4AFE-3620-4CDD-8FC2-DD0F05679EA2Q30250273-25D44DE3-4C2F-4853-BB88-A7B8D9EDF30FQ33838356-60709220-AC5F-40D2-A103-8975F01CAEE1Q33925672-2B902851-C769-4012-B540-BA51915051FAQ33943277-4C3B660D-EA47-401B-AFF4-1DC33B08A8B7Q34229555-7A965385-5FA5-4C35-B5A4-7BCF9BB6E9FEQ34555386-F7C189CF-FE04-4F2E-B0C9-07066B78AE25Q34665691-9F1CC308-A71A-4F9C-AC15-D15DA306DBEEQ34993145-A64316F7-6070-48DE-AF6A-6C52FEF13CCCQ35016157-35261413-56A3-4EDC-9D01-84E2FEA8F617Q35576181-45CF7080-1349-4278-BE39-6FB69FCBA256Q35909096-2D59B188-9318-4C60-9754-3BA351A8497CQ36053792-293EC876-A52D-4304-B1B2-2240F4E6209AQ36200300-E43B5F5D-2152-45CB-9C87-FB352CA102AAQ36362951-500B000C-2EED-454D-9AFD-92BB9F01D205Q36865880-B8E2BA53-E226-4AC5-B711-B8AE831D3BCAQ37221579-904BF7D1-3020-4DA3-8860-6E94B7681EA2Q37623389-354123E9-9B4C-4347-B7FE-84C75E3223BEQ37643136-8B70C5B5-6ED9-4BF6-A229-2900C3816194Q37701978-952B1F00-8B17-4EB0-A4CD-0D1844F6EF42Q37709456-4FAAA4C9-B0EE-4EF8-85A6-F2016400CFC3Q38200564-C826CB4C-BD2B-4BB9-B622-D841968C4030Q38241761-78B219AF-B4D8-4F3C-A8C6-B7390FFF4907Q38241988-E1CB7F25-E270-457C-A2DA-7438359DD5A1Q38251339-42CA3135-C34D-4629-97D4-ADB18CBB90D6Q38272140-ED6EE3E5-FD39-494B-B49A-73160981632FQ38284045-CFFDA6C3-BF14-4D65-83B0-704B11649C83Q38357132-2856F559-706F-4D0E-89F9-D12E2F1150AEQ38428692-67486757-CDF6-49C5-A98B-527C61351EB7Q38569175-5F0515A1-94D9-478F-91FE-C4DD287D79E8Q38664735-BF137C00-55D9-47E9-84B7-B963734641E0Q38675400-0D4DCAC8-94C3-4544-A656-222A36CF553AQ38767583-75357BBF-C435-4069-8B40-B556D81EB4B7Q38824987-D89E7DF7-5633-4483-BCDC-63E9DF9B4ECFQ38913785-A09EF13E-391C-42FA-B8BC-1DDDFAFFBF5CQ38967853-F57691D6-90B3-45FA-AD94-B650FFBC9CCFQ38989349-735DE3A6-2AEF-4086-8210-B70CB8C1A64DQ39175665-7D406CC1-4146-42EE-B9B0-47BB8006EDD0Q39411949-0C483823-600B-42E8-82B3-DD2090688E66
P2860
Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Crenolanib is a potent inhibit ...... tance-conferring point mutants
@en
Crenolanib is a potent inhibit ...... ance-conferring point mutants.
@nl
type
label
Crenolanib is a potent inhibit ...... tance-conferring point mutants
@en
Crenolanib is a potent inhibit ...... ance-conferring point mutants.
@nl
prefLabel
Crenolanib is a potent inhibit ...... tance-conferring point mutants
@en
Crenolanib is a potent inhibit ...... ance-conferring point mutants.
@nl
P2093
P2860
P1433
P1476
Crenolanib is a potent inhibit ...... tance-conferring point mutants
@en
P2093
Abhijit Ramachandran
Allison Galanis
Donald Small
Mark Levis
Trivikram Rajkhowa
P2860
P304
P356
10.1182/BLOOD-2013-10-529313
P407
P577
2013-11-13T00:00:00Z